Skip to main content

minocycline

Generic: MINOCYCLINE HYDROCHLORIDE·Brand: AMZEEQ, ARESTIN, Amzeeq, Arestin, DYNACIN, EMROSI, Emrosi, MINOCIN, MINOCYCLINE HYDROCHLORIDE, MINOLIRA, SOLODYN, XIMINO, ZILXI, Zilxi

minocycline: developed by 1 company · 3 clinical trials tracked · 2 FDA decisions.

minocycline evidence translation

What we can confirm

2 FDA records · 3 tracked trials

What it means

Source-backed records connect minocycline to DERM; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could minocycline → DERM affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 2 study sponsors

Related indications

Inflammatory lesions of rosacea in adultsCystic FibrosisStroke
Development Pipeline (1)
CompanyPhase
Journey Medical Corp (DERM)
Inflammatory lesions of rosacea in adults
Approved
Clinical Trials (3)

Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial

NCT07237048·Phase 2·CRNX
Recruiting

Primary endpoint: Change in National Institutes of Health Stroke Scale (NIHSS) Score at Day 7 post stroke

InterventionalRandomizedsingle1,164 targetStarted 2026-02Completion 2028-121 site · United StatesJoyce Chen

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

NCT06120140·Phase 2
Active, not recruiting

Primary endpoint: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment

InterventionalRandomizedopen305 targetStarted 2024-02Completion 2032-0150 sites · Argentina, Brazil, China, United StatesJanssen Research & Development, LLC

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629·Phase 2·BHC
Completed

Primary endpoint: Proportion of STAR-TER subjects with a negative MRSA culture at Day 28 vs. observational arm of historic STAR-Too trial

Interventionalopen37 enrolledStarted 2018-04Completion 2026-019 sites · United StatesUniversity of North Carolina, Chapel Hill
FDA Decisions2 records
Approval1 INDICATIONS AND USAGE ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults [see Clinical Studies ( 14 )] . Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated [see Warnings and Precautions ( 5.14 )] . ZILXI is a tetracycline-class drug indicated for th(DERM)FDA ↗
NDA213690Type 5 - New Formulation or New ManufacturerStandardTopicalAerosol, Foam
Approval(DERM)FDA ↗
NDA201922Type 3 - New Dosage FormStandardOralCapsule, Extended Release

Frequently asked questions

Who is developing minocycline?

minocycline is being developed by Journey Medical Corp.

How many clinical trials involve minocycline?

BioSniper tracks 3 clinical trials involving minocycline.

What is minocycline's latest FDA decision?

The most recent tracked FDA decision for minocycline is Approval for 1 INDICATIONS AND USAGE ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults [see Clinical Studies ( 14 )] . Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated [see Warnings and Precautions ( 5.14 )] . ZILXI is a tetracycline-class drug indicated for th, dated May 28, 2020.